- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.05. | IDL Diagnostics AB: AroCell changes name to IDL Diagnostics AB | 106 | GlobeNewswire (Europe) | AroCell AB (publ) today announces that the company will change its name to IDL Diagnostics AB in accordance with a resolution made at AroCell's Annual General Meeting on 15 May 2025. On 27 May, trading... ► Artikel lesen | |
| 26.05. | Change of company name and ticker for AroCell AB | 175 | GlobeNewswire | As from May 27, 2025, AroCell AB will change company name to IDL Diagnostics AB (publ).
Old company name: AroCell AB
New company name: IDL Diagnostics AB (publ)
Old ticker: AROC
New... ► Artikel lesen | |
| IDL DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 15.05. | AroCell AB: Report from AroCell's Annual General Meeting 2025 | 172 | GlobeNewswire (Europe) | (Available in Swedish only)
Nedan redovisas de väsentliga beslut som fattades vid AroCells årsstämma tidigare idag den 15 maj 2025. Stämman hölls i AroCells lokaler i Stockholm samt genom poströstning.... ► Artikel lesen | |
| 07.05. | AroCell AB: AroCell AB (publ) Interim Report January 1st to March 31st, 2025 | 72 | GlobeNewswire (Europe) | A word from the CEO"AroCell experienced a high level of activity during the first quarter of the year. Sales continue to grow in both oncology and bacteriology and order intake is also showing a continued... ► Artikel lesen | |
| 11.04. | AroCell AB: AroCell's board of directors proposes to the AGM that the parent company change its name to IDL Diagnostics AB | 95 | GlobeNewswire (Europe) | The board proposes to the annual general meeting (AGM) that AroCell AB changes its name to IDL Diagnostics AB. The main purpose of the name change is to create a stronger connection to the diagnostics... ► Artikel lesen | |
| 19.02. | AroCell AB: AroCell AB (publ) Interim Report January 1st to December 31st, 2024 | 117 | GlobeNewswire (Europe) | A word from the CEO" It is with great pleasure that I present this year's results. The year has been characterized by continuous and strong sales growth. We have increased our sales by over 33% compared... ► Artikel lesen | |
| 08.01. | AroCell AB: Ellen Dittberner returns as CFO at AroCell on January 13, 2025 | 98 | GlobeNewswire (Europe) | AroCell AB is pleased to announce that Ellen Dittberner will return to her role as Chief Financial Officer (CFO) on January 13, 2025, after being on parental leave since February 2024. Ellen, who has... ► Artikel lesen | |
| 24.10.24 | AroCell AB: AroCell AB (publ) Interim Report January 1st to September 30th, 2024 | 210 | GlobeNewswire (Europe) | CEO's statement"It is with great pleasure that I present another strong quarterly report. We have achieved positive net earnings, excluding goodwill amortization, and are now well on our way to sustainable... ► Artikel lesen | |
| 21.08.24 | AroCell AB: AroCell AB (publ) Interim Report January 1st to June 30th, 2024 | 163 | GlobeNewswire (Europe) | CEO's statement"I am very pleased to announce that our growth focus within existing markets is yielding results. We are experiencing a significant increase in sales while simultaneously adjusting our... ► Artikel lesen |
9 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 98,80 | +0,13 % | Gilead Sciences: Advancing New Ways To Help End the HIV Epidemic Is the Focus of This Installment of "The Centrifuge Sessions" | NORTHAMPTON, MA / ACCESS Newswire / June 5, 2025 / At Gilead, we're advancing new ways to help end the HIV epidemic by delivering innovative therapies to those who need them most. In our latest episode... ► Artikel lesen | |
| TILRAY BRANDS | 0,357 | +0,11 % | Tilray Brands Inc: Tilray Brands to be deleted from S&P/TSX Composite | ||
| VERTEX PHARMACEUTICALS | 395,50 | +0,08 % | Vertex Pharmaceuticals Incorporated: Vertex Presents New Data on Benefits of ALYFTREK and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference | - Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with... ► Artikel lesen | |
| DIGICANN VENTURES | 0,004 | 0,00 % | Digicann Ventures Inc.: Digicann Ventures Provides Update Regarding Proposed RTO Transaction | / Not for distribution to U.S. news wire services or for dissemination in the United States / VANCOUVER, British Columbia, April 22, 2025 (GLOBE NEWSWIRE) -- Digicann Ventures Ltd. ("Digicann" or... ► Artikel lesen | |
| WPD PHARMACEUTICALS | 0,002 | 0,00 % | CSE Bulletin: Consolidation - WPD Pharmaceuticals Inc. (WBIO) | le 23 décembre/December 2024
WPD Pharmaceuticals Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every twenty-five... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 36,000 | +1,12 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction | Investigator-initiated Phase 2 trial to evaluate TNX-102 SL's potential to reduce severity of acute stress reaction (ASR) and frequency of acute stress disorder (ASD) Trial is sponsored by the University... ► Artikel lesen | |
| TITAN PHARMACEUTICALS | 0,001 | -100,00 % | Titan Pharmaceuticals, Inc.: Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd. | NEW YORK, June 03, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced today the filing by Black Titan Corporation with the U.S. Securities and... ► Artikel lesen | |
| BAYER | 26,435 | +0,02 % | Bayer, Deutsche Bank, Volkswagen und Co: Unterbewertete deutsche Aktien mit Comeback-Potenzial | Die Rheinmetall-Aktie ist in diesem Jahr bereits um 200 Prozent gestiegen. Doch nicht jede deutsche Aktie kann eine solche Performance aufweisen. Wie es bei Bayer, Deutsche Bank, Volkswagen und Co steht... ► Artikel lesen | |
| MERCK KGAA | 115,20 | -0,17 % | JPMORGAN stuft MERCK KGAA auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Merck KGaA mit einem Kursziel von 155 Euro auf "Overweight" belassen. Die auf der Asco-Krebsforschertagung präsentierten Studiendaten... ► Artikel lesen | |
| GSK | 18,050 | -0,03 % | BERENBERG stuft GSK auf 'Hold' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat GSK nach gutem Lauf bei unverändertem Kursziel von 1600 Pence von "Buy" auf "Hold" abgestuft. Die Kursentwicklung des Pharmakonzerns sei in... ► Artikel lesen | |
| NOVO NORDISK | 65,55 | +2,49 % | Novo Nordisk stark: Gelingt jetzt der Ausbruch? | Die Aktie von Novo Nordisk hat sich in den vergangenen Monaten alles andere als gut entwickelt. Mehr als 60 Prozent hat das Papier seit Juli vergangenen Jahres an Wert eingebüßt. Nun scheint sich aber... ► Artikel lesen | |
| PFIZER | 20,510 | +0,15 % | JPMORGAN stuft PFIZER INC auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Pfizer anlässlich der Asco-Krebsforschertagung mit einem Kursziel von 30 US-Dollar auf "Neutral" belassen. Die Onkologie-Pipeline... ► Artikel lesen | |
| METSERA | 27,490 | -4,12 % | Metsera, Inc.: Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association | ||
| SANOFI | 89,11 | +0,01 % | Milliardendeal: Sanofi kauft Blueprint Medicines - AKTIONÄR-Leser kassieren | In der aktuellen Ausgabe 23/2025 hat DER AKTIONÄR das Thema Übernahme-Chancen im Biotech-Sektor beleuchtet und hier drei spannenden Übernahmekandidaten vorgestellt. Am heutigen Montag kam es zum ersten... ► Artikel lesen | |
| EDWARDS LIFESCIENCES | 67,46 | -0,82 % | Is Edwards Lifesciences Stock Underperforming the Dow? |
IDL DIAGNOSTICS AB gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell -9,39 % bei einem Aktienkurs von 0,039 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IDL DIAGNOSTICS AB finden Sie auf Wallstreet Online.